Frédéric Oudéa, current CEO of Societe Generale who is due to leave office in May 2023, will be proposed as the next non-executive chairman of the board of directors of Sanofi, the pharmaceutical group announced in a press release on Monday.
Sanofi indicates that Mr. Ouda was appointed censor by the group’s board of directors on September 2, and that his appointment as director will be proposed at the next general meeting of shareholders.
following this general meeting – the precise date of which has not yet been set but which is usually held in the spring – it will be proposed to the Sanofi Board of Directors the appointment of Frdric Ouda as non-executive chairman of this board, replacing Serge Weinberg whose mandate will have arrived by chance.
Frdric Ouda has announced that he will leave his position as Chief Executive Officer and Director of Socit Generale in May 2023, at the end of his current mandate, recalls Sanofi in its press release.
Frdric Ouda and Paul Hudson, CEO of Sanofi, will form an excellent duo to position Sanofi as a modern healthcare company and strengthen its position as a French, European and global leader in the service of patients, commented Serge Weinberg, quoted in the press release.
Nobanques: the cheapest offers to control your budget
I am very happy to join Sanofi’s Board of Directors as a non-voting member, with, subject to the agreement of its shareholders, the prospect of taking over as Chairman. I am extremely motivated by the prospect of contributing in the coming years to the strategy and sustainable development of Sanofi, a leading company in a strategic health sector, with a strong impact and in full transformation, and to be the guarantor of the quality of the governance of the group, for his part declared Mr. Ouda.